, Tracking Stock Market Picks
Enter Symbol:
Immune Pharmaceuticals Inc. (IMNP) [hlAlert]

EpiCept Corporation (EpiCept) is a specialty pharmaceutical company focused on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. It focuses its clinical development efforts on cancer therapies and topically delivered analgesics targeting peripheral nerve receptors. Its lead product
is Ceplene, which when used concomitantly with low-dose interleukin-2 (IL-2) is intended as remission maintenance therapy in the treatment of acute myeloid leukemia (AML) for adult patients who are in their first complete remission. In addition to Ceplene, EpiCept has two other oncology compounds, including crolibulin, a small molecule vascular disruption agent (VDA), and apoptosis inducer for the treatment of patients with solid tumors and Azixa, an apoptosis inducer with VDA activity, which is in Phase II clinical trials in patients with primary glioblastoma and cancer that has metastasized to the brain.
( Total: 3 Current Stock Recommendations )
Immune Pharmaceuticals Inc.   (3)
Buy 100%
Related companies

* As of 8/27/2015 12:00 AM
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy